LGND Q2 2021 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$85M+104.4% YoY

Gross Profit

$54M63.9% margin

Operating Income

$46M54.0% margin

Net Income

$31M36.3% margin

EPS (Diluted)

$1.79

QoQ Revenue Growth

+53.5%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

$16M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$470M

Stockholders' Equity

$787M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$85M	$41M	+104.4%
Gross Profit	$54M	$34M	+60.1%
Operating Income	$46M	$7M	+544.2%
Net Income	$31M	$22M	+39.1%

Revenue Segments

Material Sales, Captisol

$63M59%

Contract Revenue

$14M13%

Royalty

$9M8%

Contract Revenue, Service

$7M7%

Kyprolis

$5M5%

Milestone

$4M3%

Evomela

$2M2%

License Fees, Milestones, and Product, Other, Product, Other

$2M1%

License Fees

$1M1%

Royalty, Other

$983,0001%